ArticleFrontiers in endocrinology2026
Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is a novel, reliable indicator of dyslipidemia. However, its association with cardiac outcomes in patients with type 2 diabetes mellitus (T2DM) following percutaneous coronary intervention (PCI) remains unclear. We investigated the association of the NHHR with the risks of major adverse cardiovascular events (MACEs) following PCI in adults with T2DM. Methods: This retrospective cohort study included 1176 adults with T2DM undergoing PCI after new-onset acute myocardial infarction between January 1, 2019, and December 31, 2023. Patients were categorized into NHHR quartiles. The relationship between the NHHR and post-PCI MACE risk was investigated using univariate and multivariate Cox regression analyses. Restricted cubic splines and smooth curve fitting evaluated the nonlinear association between the NHHR and MACE risk; receiver operating characteristic (ROC) curves determined the prognostic significance of the NHHR. Results: Over 21.0 ± 6.6 months, 246 MACEs occurred. In multivariate analysis, the NHHR was associated with MACE incidence, even after adjustments (vs. group Q1: hazard ratio [95% confidence interval] in groups Q3 and Q4, 4.00 [2.47-6.48] and 6.28 [3.92-10.05], respectively; both Conclusions: Our findings suggested a nonlinear positive association between NHHR and MACE risk in T2DM patients undergoing PCI. Routine NHHR assessment may facilitate early risk identification and tailored care for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.